Gastrointestinal Cancer | Specialty

Dr. Simeone on the Importance of Mutational Analysis in Patients With Pancreatic Cancer

May 5th 2018

Diane Simeone, MD, director, Pancreatic Cancer Center, associate director, Translational Research, NYU Langone’s Perlmutter Cancer Center, discusses the importance of mutational analysis in the treatment of patients with pancreatic cancer.

Marshall Highlights Durable Benefits of Pembrolizumab in GI Cancers

May 3rd 2018

Immunotherapy has arrived in the gastrointestinal cancer landscape, and while not all patients will benefit from these agents, those who do are likely to have long-lasting responses, explained John L. Marshall, MD.

Dr. Collisson on the Difficulty of Diagnosing Cholangiocarcinoma

May 3rd 2018

Eric A. Collisson, MD, associate professor, Department of Medicine, University of California, San Francisco Helen Diller Comprehensive Cancer Center, discusses the difficulty of diagnosing cholangiocarinoma.

Dr. Oberstein on PEGPH20 in Patients With Pancreatic Cancer

May 3rd 2018

Paul E. Oberstein, MD, assistant professor of medicine, assistant director, Pancreatic Cancer Center, director, Gastrointestinal Medical Oncology Program, NYU Langone’s Perlmutter Cancer Center, discusses the use of PEGPH20 in advanced pancreatic cancer.

Dr. Beatty on the Potential for Immunotherapy in GI Malignancies

May 2nd 2018

Gregory L. Beatty, MD, PhD, assistant professor of medicine, director of Tanslation Research, Pancreatic Cancer Research Center, University of Pennsylvania Perelman School of Medicine, discusses the potential for immunotherapy in gastrointestinal malignancies.

Dr. Welling on SIRT in Patients With Hepatobiliary Neoplasms

May 1st 2018

Theodore H. Welling MD, associate professor, department of Surgery, director, Liver Tumor Program, NYU Langone’s Perlmutter Cancer Center, discusses the use of selective internal radiation therapy (SIRT) in patients with hepatobiliary cancers.

Dr. Simeone on Emerging Subtypes of Pancreatic Cancer

May 1st 2018

Diane Simeone, MD, director, Pancreatic Cancer Center, associate director, Translational Research, NYU Langone’s Perlmutter Cancer Center, discusses emerging subtypes of pancreatic cancer.

Regorafenib HCC Benefits Consistent in Additional Analyses

April 30th 2018

Second-line regorafenib (Stivarga) continued to show antitumor activity regardless of prior dose or time to progression on frontline sorafenib (Nexavar) for patients with unresectable advanced hepatocellular carcinoma.

Dr. Atreya on Questions Remaining With Tumor Sidedness in CRC

April 25th 2018

Chloe E. Atreya, MD, PhD, assistant clinical professor, Department of Medicine, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses questions regarding sidedness in colorectal cancer.

Dr. Simeone Discusses Unmet Needs in Pancreatic Cancer

April 24th 2018

Diane Simeone, MD, director, Pancreatic Cancer Center, associate director, Translational Research, NYU Langone’s Perlmutter Cancer Center, discusses unmet needs in the treatment of patients with pancreatic cancer.

HCC: Emerging Therapies

April 24th 2018

Use of Immunotherapy for HCC

April 24th 2018

Clinical Use of Regorafenib in mHCC

April 24th 2018

Treatment of Relapsed/Refractory mHCC

April 24th 2018

First-Line Therapy in Advanced HCC

April 24th 2018

When to Move to Systemic Therapy in HCC

April 24th 2018

HCC: Role of Radiotherapy and Measuring Response

April 24th 2018

When to Use Locoregional Therapies in HCC

April 24th 2018

HCC: Criteria for Resection and Adjuvant Therapy

April 24th 2018

Multidisciplinary Team Approach to Treating HCC

April 24th 2018